Zobrazeno 1 - 10
of 1 661
pro vyhledávání: '"P. Ascierto"'
Autor:
Alessandro Lavoro, Luca Falzone, Giuseppe Gattuso, Giuseppe N. Conti, Rosario Caltabiano, Gabriele Madonna, Mariaelena Capone, James A. McCubrey, Paolo A. Ascierto, Massimo Libra, Saverio Candido
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-20 (2024)
Abstract Background Cancer onset and progression are driven by genetic and epigenetic alterations leading to oncogene activation and the silencing of tumor suppressor genes. Among epigenetic mechanisms, DNA methylation (methDNA) is gaining growing in
Externí odkaz:
https://doaj.org/article/aceb0e12d2e74b42a6c2049cf1cf8200
Autor:
Pedro J Romero, Bernard A Fox, Iman Osman, Omid Hamid, Paolo A Ascierto, Michael T Lotze, Jason John Luke, James J Mulé
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 9 (2024)
Externí odkaz:
https://doaj.org/article/85e7b8c75928474dbab1de8b38426b34
Autor:
Alberto Mendoza‐Valderrey, Jane Choe, Daria M. Kessler, Gianna Jimenez, Xinmin Li, Steven Kolker, Warren Allen, Jennifer A. Linehan, Przemyslaw W. Twardowski, Maria Libera Ascierto
Publikováno v:
Cancer Medicine, Vol 13, Iss 15, Pp n/a-n/a (2024)
Abstract Background Neoadjuvant cisplatin‐based chemotherapy (NAC) followed by cystectomy is the standard of care for patients with muscle‐invasive bladder cancer (MIBC). Pathologic complete response (pCR) is associated with favorable outcomes, b
Externí odkaz:
https://doaj.org/article/02d7ef7048a2464ca5aae28cc305f034
Autor:
Alexandra Leary, Paolo A Ascierto, Michele Maio, Georgia Kollia, Jennifer Friedmann, Marina Tschaika, Patrick Schöffski, Jonathan Baden, Neeltje Steeghs, Parul Doshi, Massimo Di Nicola, Jean-Pierre Delord, Iwona Lugowska, Mauricio Burotto, David S P Tan, Anthony Gonçalves, Michael Schenker, Ning Huang, Tudor-Eliade Ciuleanu, Martin Richardet, Lorena Lupinacci, Julieta Grasselli, Jacqueline Vuky, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Misena Pacius, Quyen Duong
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 8 (2024)
Background Checkpoint inhibitor therapy has demonstrated overall survival benefit in multiple tumor types. Tumor mutational burden (TMB) is a predictive biomarker for response to immunotherapies. This study evaluated the efficacy of nivolumab+ipilimu
Externí odkaz:
https://doaj.org/article/be397a2c9d104c41b010a59bc9500941
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-10 (2024)
Abstract Most anti-cancer modalities are designed to directly kill cancer cells deploying mechanisms of action (MOAs) centered on the presence of a precise target on cancer cells. The efficacy of these approaches is limited because the rapidly evolvi
Externí odkaz:
https://doaj.org/article/c7f24b5e303f415da284173bc18ae73a
Autor:
Domenico Liguoro, Rachele Frigerio, Arianna Ortolano, Andrea Sacconi, Mario Acunzo, Giulia Romano, Giovanni Nigita, Barbara Bellei, Gabriele Madonna, Mariaelena Capone, Paolo Antonio Ascierto, Rita Mancini, Gennaro Ciliberto, Luigi Fattore
Publikováno v:
Cell Death and Disease, Vol 15, Iss 3, Pp 1-11 (2024)
Abstract Therapy of melanoma has improved dramatically over the last years thanks to the development of targeted therapies (MAPKi) and immunotherapies. However, drug resistance continues to limit the efficacy of these therapies. Our research group ha
Externí odkaz:
https://doaj.org/article/23532b4e96e84353911fe01ac65d5358
Autor:
Luigi Scarpato, Marco Palla, Sabino Strippoli, Luca Tagliaferri, Luca Fania, Maristella Saponara, Anna Carbone, Francesco Spagnolo, Flavia Silvestri, Paolo Antonio Ascierto
Publikováno v:
Dermatology Reports (2024)
Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multiple studies demonstrated that the aberrant activation of Hedgehog signaling is a driver of BCC development, and its blockade represents a potential therapeutic
Externí odkaz:
https://doaj.org/article/532de72c851f4cdb8b02316ca70fc097
Autor:
Jarushka Naidoo, Igor Puzanov, Paolo A Ascierto, Marc S Ernstoff, Douglas B Johnson, Fei Ye, Mitchell S von Itzstein, David E Gerber, Benjamin Switzer, Aliyah Pabani, Hannah Burnette, Run Fan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 5 (2024)
Background Artificial intelligence (AI) chatbots have become a major source of general and medical information, though their accuracy and completeness are still being assessed. Their utility to answer questions surrounding immune-related adverse even
Externí odkaz:
https://doaj.org/article/10149fdee8db4c7899ea1632bcd5d0b9
Autor:
Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo D. d’Arienzo, Florentia Mina, Juliane A. Czapla, Aleigha R. Lawless, Eleonora Bongiovanni, Umberto Santaniello, Helena Zappi, Dominika Dulak, Andrew Williamson, Rebecca Lee, Avinash Gupta, Caili Li, Lu Si, Martina Ubaldi, Naoya Yamazaki, Dai Ogata, Rebecca Johnson, Benjamin C. Park, Seungyeon Jung, Gabriele Madonna, Juliane Hochherz, Yoshiyasu Umeda, Yasuhiro Nakamura, Christoffer Gebhardt, Lucia Festino, Mariaelena Capone, Paolo Antonio Ascierto, Douglas B. Johnson, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies, Kenjiro Namikawa, Mario Mandala, Jun Guo, Paul Lorigan, Yana G. Najjar, Andrew Haydon, Pietro Quaglino, Genevieve M. Boland, Ryan J. Sullivan, Andrew J.S. Furness, Ruth Plummer, Keith T. Flaherty
Publikováno v:
EClinicalMedicine, Vol 71, Iss , Pp 102564- (2024)
Externí odkaz:
https://doaj.org/article/377d8aad4882472db54c2cd4b6fbb9b1
Autor:
Paolo A. Ascierto, Milena Casula, Jenny Bulgarelli, Marina Pisano, Claudia Piccinini, Luisa Piccin, Antonio Cossu, Mario Mandalà, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbe, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F. Sanmamed, Domenico Mallardo, Miriam Paone, Maria Grazia Vitale, Ignacio Melero, Antonio M. Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni, Giuseppe Palmieri
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract No prospective data were available prior to 2021 to inform selection between combination BRAF and MEK inhibition versus dual blockade of programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) as first-line treat
Externí odkaz:
https://doaj.org/article/2b98c18ea9d84e45baec87cc1752497f